TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 22500920

Group type: EXPERIMENTAL
Intervention: Myfenax(®) (Teva)
Number of subjects: 43

Group type: COMPARATOR
Intervention: CellCept(®) (Roche)
Number of subjects: 43

Group type: EXPERIMENTAL
Intervention: Both Myfenax(®) and CellCept(®)
Number of subjects: 43
Study: 20727522

Group type: EXPERIMENTAL
Intervention: n-3 supplementation (1.2g/day for 3 months)
Number of subjects: 25

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 25
Study: 18480626

Group type: EXPERIMENTAL
Intervention: 60 mg lidocaine suppository 2 h before biopsy
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: 120 mg lidocaine suppository 1 h before biopsy
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: 120 mg lidocaine suppository 2 h before biopsy
Number of subjects: 100

Group type: COMPARATOR
Intervention: Periprostatic infiltration of 5 ml 2% lidocaine
Number of subjects: 100
Study: 15630488

Group type: EXPERIMENTAL
Intervention: Intravenous thrombolysis
Number of subjects: 39

Group type: COMPARATOR
Intervention: Stenting
Number of subjects: 39
Study: 12859158

Group type: EXPERIMENTAL
Intervention: Losartan (50 mg for 5 weeks, then 100 mg for 5 weeks)
Number of subjects: 147

Group type: EXPERIMENTAL
Intervention: Losartan (100 mg after 5 weeks)
Number of subjects: 147

Group type: EXPERIMENTAL
Intervention: Losartan
Number of subjects: 147

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 147
Study: 10634658

Group type: EXPERIMENTAL
Intervention: Screening with chest radiography
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: CT screening for lung cancer
Number of subjects: 0
Study: 8611830

Group type: EXPERIMENTAL
Intervention: Single daily dose of aminoglycosides
Number of subjects: 3091

Group type: COMPARATOR
Intervention: Multiple daily doses of aminoglycosides
Number of subjects: 3091
Study: 1735651

Group type: EXPERIMENTAL
Intervention: Two types of head coverings (specific types not mentioned)
Number of subjects: 81

Group type: COMPARATOR
Intervention: No head coverings (control group)
Number of subjects: 81

Group type: EXPERIMENTAL
Intervention: Patients who reached normothermia in 5 hours or less (subgroup analysis)
Number of subjects: 81
Study: 6384785

Group type: EXPERIMENTAL
Intervention: Methylprednisolone
Number of subjects: 59

Group type: EXPERIMENTAL
Intervention: Dexamethasone
Number of subjects: 59

Group type: COMPARATOR
Intervention: Control
Number of subjects: 59

Group type: EXPERIMENTAL
Intervention: Corticosteroids (combined)
Number of subjects: 59
Study: 31774954

Group type: EXPERIMENTAL
Intervention: MRI-invitation group
Number of subjects: 40373

Group type: COMPARATOR
Intervention: Mammography-only group
Number of subjects: 40373

Group type: EXPERIMENTAL
Intervention: MRI-invitation group (those who underwent MRI)
Number of subjects: 40373

Group type: EXPERIMENTAL
Intervention: MRI-invitation group (those who did not accept MRI)
Number of subjects: 40373

Group type: EXPERIMENTAL
Intervention: MRI screening
Number of subjects: 40373

Group type: EXPERIMENTAL
Intervention: MRI recall for additional testing
Number of subjects: 40373

Group type: EXPERIMENTAL
Intervention: MRI biopsy
Number of subjects: 40373
Study: 27718369

Group type: EXPERIMENTAL
Intervention: Ketamine (single infusion of sub-anesthetic dose)
Number of subjects: 80
Study: 26202488

Group type: EXPERIMENTAL
Intervention: Denosumab treatment for 8 years (long-term group)
Number of subjects: 4550

Group type: EXPERIMENTAL
Intervention: Denosumab treatment for 5 years (cross-over group)
Number of subjects: 4550

Group type: EXPERIMENTAL
Intervention: Denosumab treatment (both groups)
Number of subjects: 4550
Study: 24411313

Group type: EXPERIMENTAL
Intervention: Prenotification postcard present
Number of subjects: 3010

Group type: COMPARATOR
Intervention: Prenotification postcard absent
Number of subjects: 3010

Group type: EXPERIMENTAL
Intervention: Teaser present
Number of subjects: 3010

Group type: COMPARATOR
Intervention: Teaser absent
Number of subjects: 3010

Group type: EXPERIMENTAL
Intervention: Older participants
Number of subjects: 3010

Group type: EXPERIMENTAL
Intervention: Females with teaser
Number of subjects: 3010

Group type: EXPERIMENTAL
Intervention: Higher response rates with postcard
Number of subjects: 3010
Study: 23176888

Group type: EXPERIMENTAL
Intervention: Early interventional treatment with mometasone furoate nasal spray (EIT group)
Number of subjects: 75

Group type: COMPARATOR
Intervention: Postonset treatment with mometasone furoate nasal spray (POT group)
Number of subjects: 75

Group type: COMPARATOR
Intervention: Placebo treatment (placebo group)
Number of subjects: 75
Study: 19384690

Group type: EXPERIMENTAL
Intervention: Experimental therapies
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Optimal two-stage design
Number of subjects: 0
Study: 17080503

Group type: EXPERIMENTAL
Intervention: High-throughput HPLC-FLD method for furosemide determination
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: High-throughput HPLC-FLD method for norfloxacin determination
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Method applied to bioequivalence study of two furosemide-containing formulations
Number of subjects: 0
Study: 15160519

Group type: EXPERIMENTAL
Intervention: Antibiotic prophylaxis
Number of subjects: 124

Group type: COMPARATOR
Intervention: No antibiotic prophylaxis
Number of subjects: 124
Study: 11070330

Group type: EXPERIMENTAL
Intervention: LHRH (800 microg/day over 2 weeks)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: LHRH (400 microg acute administration)
Number of subjects: 20
Study: 9041232

Group type: EXPERIMENTAL
Intervention: Zileuton (600 mg qid)
Number of subjects: 305

Group type: EXPERIMENTAL
Intervention: Mesalazine (400 mg qid)
Number of subjects: 305

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 305

Group type: EXPERIMENTAL
Intervention: Mesalazine
Number of subjects: 305
Study: 8178840

Group type: EXPERIMENTAL
Intervention: Conjugated estrogens (0.625 mg) with medroxyprogesterone acetate (2.5 mg daily)
Number of subjects: 1724

Group type: EXPERIMENTAL
Intervention: Conjugated estrogens (0.625 mg) with medroxyprogesterone acetate (5.0 mg daily)
Number of subjects: 1724

Group type: EXPERIMENTAL
Intervention: Conjugated estrogens (0.625 mg) with medroxyprogesterone acetate (5.0 mg for 14 days per 28-day cycle)
Number of subjects: 1724

Group type: EXPERIMENTAL
Intervention: Conjugated estrogens (0.625 mg) with medroxyprogesterone acetate (10.0 mg for 14 days per 28-day cycle)
Number of subjects: 1724

Group type: COMPARATOR
Intervention: Conjugated estrogens (0.625 mg) alone
Number of subjects: 1724
Study: 3228824

Group type: EXPERIMENTAL
Intervention: 50 mg slow‐release isosorbide‐5‐mononitrate (ISMN SR) once daily
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: 20 mg nifedipine SR twice daily
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Combination of both drugs
Number of subjects: 18

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18
Study: 30012938

Group type: EXPERIMENTAL
Intervention: Limaprost
Number of subjects: 46

Group type: COMPARATOR
Intervention: Pregabalin
Number of subjects: 46
Study: 28780559

Group type: EXPERIMENTAL
Intervention: Low-energy total diet replacement programme (810 kcal/d) for 8 weeks, followed by gradual food reintroduction and weekly behavioural support for 24 weeks.
Number of subjects: 0

Group type: COMPARATOR
Intervention: Usual weight management interventions delivered in primary care.
Number of subjects: 0
Study: 25000214

Group type: EXPERIMENTAL
Intervention: Pregabalin 150 mg
Number of subjects: 52

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 52
Study: 23810723

Group type: EXPERIMENTAL
Intervention: Budesonide (3 mg twice or 3 times daily) with azathioprine (1-2 mg/kg/day)
Number of subjects: 46

Group type: COMPARATOR
Intervention: Prednisone (40 mg/day tapered to 10 mg/day) with azathioprine (1-2 mg/kg/day)
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: Open-label budesonide treatment after 6 months
Number of subjects: 46
Study: 21081959

Group type: EXPERIMENTAL
Intervention: HKBBST
Number of subjects: 129
Study: 19033530

Group type: EXPERIMENTAL
Intervention: Lubiprostone 24 microg per day
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study: 17519073

Group type: EXPERIMENTAL
Intervention: Triple-bead mixed amphetamine salts 37.5 mg
Number of subjects: 0
Study: 15554316

Group type: EXPERIMENTAL
Intervention: Inactivated influenza vaccine
Number of subjects: 158451

Group type: EXPERIMENTAL
Intervention: Mass immunization of children
Number of subjects: 158451
Study: 11464179

Group type: EXPERIMENTAL
Intervention: Micronized isotretinoin 0.4 mg/kg once daily without food (n = 300)
Number of subjects: 600

Group type: COMPARATOR
Intervention: Standard isotretinoin 1.0 mg/kg per day in two divided doses with food (n = 300)
Number of subjects: 600
Study: 9516704

Group type: EXPERIMENTAL
Intervention: Desmopressin acetate (DDAVP)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo (normal saline)
Number of subjects: 0
Study: 8795509

Group type: EXPERIMENTAL
Intervention: Surgery (n = 46)
Number of subjects: 124

Group type: COMPARATOR
Intervention: Intra-arterial catheter-directed thrombolysis (n = 78) with rt-PA or UK
Number of subjects: 124

Group type: COMPARATOR
Intervention: Intra-arterial catheter-directed thrombolysis (n = 78)
Number of subjects: 124

Group type: COMPARATOR
Intervention: Prosthetic grafts
Number of subjects: 124
Study: 2266236

Group type: EXPERIMENTAL
Intervention: 0.1 M hydrochloric acid infusion
Number of subjects: 50

Group type: COMPARATOR
Intervention: Normal saline infusion
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: 1 M sodium bicarbonate infusion
Number of subjects: 50

Group type: COMPARATOR
Intervention: Healthy controls (no intervention)
Number of subjects: 50
Study: 6774493

Group type: EXPERIMENTAL
Intervention: Nitroglycerin (continuous perfusion for 48 hours, started < 8 hours after onset of symptoms)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Nitroglycerin (continuous perfusion for 48 hours, started > 8 hours after onset of symptoms)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Control group (n = 29)
Number of subjects: 60
Study: 31060146

Group type: EXPERIMENTAL
Intervention: Lifestyle intervention (diet, exercise, and diet plus exercise)
Number of subjects: 577

Group type: COMPARATOR
Intervention: Control group (non-intervention)
Number of subjects: 577
Study: 27883269

Group type: EXPERIMENTAL
Intervention: Standard six-dose AL treatment with milk (A)
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: Oil-fortified maize porridge (B)
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: Two tablets of AL
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: One tablet of AL
Number of subjects: 33
Study: 25500293

Group type: EXPERIMENTAL
Intervention: Mitral valve repair
Number of subjects: 116

Group type: COMPARATOR
Intervention: Mitral valve replacement
Number of subjects: 116
Study: 26016869

Group type: EXPERIMENTAL
Intervention: MUFAs
Number of subjects: 195

Group type: EXPERIMENTAL
Intervention: n-6 PUFAs
Number of subjects: 195

Group type: COMPARATOR
Intervention: Saturated fatty acids (SFAs)
Number of subjects: 195
Study: 23278997

Group type: EXPERIMENTAL
Intervention: Short-acting anticholinergic bronchodilation
Number of subjects: 2745

Group type: COMPARATOR
Intervention: Control (no bronchodilation)
Number of subjects: 2745
Study: 21901330

Group type: EXPERIMENTAL
Intervention: Dexmedetomidine (DEX) with a dose of 0.7 μg/kg/h after initial dose and effect-site concentration (ESC) of fentanyl of 2 ng/ml
Number of subjects: 22

Group type: COMPARATOR
Intervention: Placebo (saline) with ESC of fentanyl of 4 ng/ml
Number of subjects: 22
Study: 17349805

Group type: EXPERIMENTAL
Intervention: Context-sensitive control processes using a Stroop procedure
Number of subjects: 0

Group type: COMPARATOR
Intervention: Awareness of context manipulation
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Attention to the predictive context dimension
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Relative salience of target and predictive context dimensions
Number of subjects: 0
Study: 16427168

Group type: EXPERIMENTAL
Intervention: Stress fracture group
Number of subjects: 10

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 10
Study: 12951310

Group type: EXPERIMENTAL
Intervention: Hylan GF-20 (Synvisc)
Number of subjects: 506

Group type: COMPARATOR
Intervention: Conventional treatment
Number of subjects: 506
Study: 10848653

Group type: EXPERIMENTAL
Intervention: Omeprazole 20 mg b.d.
Number of subjects: 20

Group type: COMPARATOR
Intervention: Lansoprazole 30 mg b.d.
Number of subjects: 20
Study: 9735411

Group type: EXPERIMENTAL
Intervention: Pentoxifylline (PTX) plus standard-dose external-beam whole-brain radiation treatment (WBRT)
Number of subjects: 14

Group type: COMPARATOR
Intervention: Historical controls (not specified in detail)
Number of subjects: 14
Study: 8014294

Group type: EXPERIMENTAL
Intervention: Type 1 HME filter
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Type 2 HME filter
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Type 3 HME filter
Number of subjects: 30
Study: 2902601

Group type: EXPERIMENTAL
Intervention: Procaterol, given for a month
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 0
Study: 29720209

Group type: EXPERIMENTAL
Intervention: Implementation intervention
Number of subjects: 44
Study: 29143624

Group type: EXPERIMENTAL
Intervention: Group Antenatal Care (CenteringPregnancy-based)
Number of subjects: 222

Group type: COMPARATOR
Intervention: Individual Antenatal Care (Focused Antenatal Care - FANC)
Number of subjects: 222

Group type: EXPERIMENTAL
Intervention: Group Antenatal Care (CenteringPregnancy-based) for Muslim women
Number of subjects: 222

Group type: COMPARATOR
Intervention: Individual Antenatal Care (Focused Antenatal Care - FANC) for Muslim women
Number of subjects: 222

Group type: EXPERIMENTAL
Intervention: Group Antenatal Care (CenteringPregnancy-based) for Christian women
Number of subjects: 222

Group type: COMPARATOR
Intervention: Individual Antenatal Care (Focused Antenatal Care - FANC) for Christian women
Number of subjects: 222
Study: 26482278

Group type: EXPERIMENTAL
Intervention: Etirinotecan pegol (145 mg/m² as a 90-min intravenous infusion every 3 weeks)
Number of subjects: 852

Group type: COMPARATOR
Intervention: Treatment of physician's choice
Number of subjects: 852

Group type: EXPERIMENTAL
Intervention: Etirinotecan pegol
Number of subjects: 852
Study: 23225625

Group type: EXPERIMENTAL
Intervention: Transcranial direct current stimulation (tDCS) applied to the motor cortex during training.
Number of subjects: 0
Study: 21707533

Group type: EXPERIMENTAL
Intervention: Galantamine 16 mg/day
Number of subjects: 841

Group type: COMPARATOR
Intervention: Placebo (for patients switched from galantamine)
Number of subjects: 841

Group type: COMPARATOR
Intervention: Continuous placebo
Number of subjects: 841

Group type: EXPERIMENTAL
Intervention: Galantamine treatment (subgroup analysis)
Number of subjects: 841
Study: 17643535

Group type: EXPERIMENTAL
Intervention: Levosimendan
Number of subjects: 22

Group type: COMPARATOR
Intervention: Dobutamine
Number of subjects: 22
Study: 16929307

Group type: EXPERIMENTAL
Intervention: L-DOPA (3,4-dihydroxy-L-phenylalanine)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Haloperidol
Number of subjects: 0
Study: 12697596

Group type: EXPERIMENTAL
Intervention: Cyclizine 50 mg
Number of subjects: 99

Group type: COMPARATOR
Intervention: Dexamethasone 8 mg
Number of subjects: 99

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 99
Study: 11054514

Group type: EXPERIMENTAL
Intervention: Continuous hyperfractionated accelerated radiotherapy (V-CHART) delivering a total dose of 55.3 Gy in 33 fractions over 17 consecutive days
Number of subjects: 239

Group type: EXPERIMENTAL
Intervention: Continuous hyperfractionated accelerated radiotherapy with mitomycin C (V-CHART+MMC) with additional administration of 20 mg/m2 MMC on day 5 of treatment
Number of subjects: 239

Group type: COMPARATOR
Intervention: Conventional fractionation (CF) with 70 Gy in 7 weeks in 35 fractions
Number of subjects: 239
Study: 9375429

Group type: EXPERIMENTAL
Intervention: Directed prayer
Number of subjects: 496

Group type: EXPERIMENTAL
Intervention: Nondirected prayer
Number of subjects: 496

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 496

Group type: EXPERIMENTAL
Intervention: Agents (prayers)
Number of subjects: 496

Group type: EXPERIMENTAL
Intervention: Amount of prayer by agents
Number of subjects: 496

Group type: EXPERIMENTAL
Intervention: Objective measures
Number of subjects: 496

Group type: EXPERIMENTAL
Intervention: Subjects' belief in the power of prayer for others
Number of subjects: 496

Group type: EXPERIMENTAL
Intervention: Subjects' conviction regarding group assignment
Number of subjects: 496
Study: 7986838

Group type: EXPERIMENTAL
Intervention: Iomeprol (nonionic contrast medium)
Number of subjects: 438
Study: 3291559

Group type: EXPERIMENTAL
Intervention: Prazosin
Number of subjects: 37

Group type: EXPERIMENTAL
Intervention: Metoprolol
Number of subjects: 37
Study: 31622131

Group type: EXPERIMENTAL
Intervention: Adjuvant trastuzumab
Number of subjects: 3177
Study: 28169575

Group type: EXPERIMENTAL
Intervention: Clinician referral and 12-week exercise training program
Number of subjects: 147

Group type: COMPARATOR
Intervention: Usual care (control)
Number of subjects: 147
Study: 26573025

Group type: EXPERIMENTAL
Intervention: Mindfulness-Based Stress Reduction (MBSR) program, 8 weeks, 90-minute sessions per week
Number of subjects: 40

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 40
Study: 23206974

Group type: EXPERIMENTAL
Intervention: Booster dose administered 5 years post-vaccination
Number of subjects: 663

Group type: EXPERIMENTAL
Intervention: Booster dose administered 10 years post-vaccination
Number of subjects: 663

Group type: EXPERIMENTAL
Intervention: Booster dose administered 15 years post-vaccination
Number of subjects: 663

Group type: COMPARATOR
Intervention: No booster dose (5, 10, or 15 years post-vaccination)
Number of subjects: 663
Study: 21435876

Group type: EXPERIMENTAL
Intervention: 450 mg idebenone (Catena®)
Number of subjects: 21

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 21
Study: 18491311

Group type: EXPERIMENTAL
Intervention: Fish oil (3.5 g daily)
Number of subjects: 81

Group type: COMPARATOR
Intervention: High oleic sunflower oil (3.5 g daily)
Number of subjects: 81
Study: 16570033

Group type: EXPERIMENTAL
Intervention: Levobupivacaine 0.5%
Number of subjects: 30

Group type: COMPARATOR
Intervention: Ropivacaine 0.75%
Number of subjects: 30
Study: 14681599

Group type: EXPERIMENTAL
Intervention: Carotid endarterectomy (CEA) with primary closure
Number of subjects: 534

Group type: COMPARATOR
Intervention: Carotid endarterectomy (CEA) with patching
Number of subjects: 534

Group type: EXPERIMENTAL
Intervention: Baseline normal carotid arteries
Number of subjects: 534

Group type: EXPERIMENTAL
Intervention: Baseline CAS <50%
Number of subjects: 534

Group type: EXPERIMENTAL
Intervention: Baseline CAS 50% to 79%
Number of subjects: 534

Group type: EXPERIMENTAL
Intervention: Late neurologic events
Number of subjects: 534

Group type: EXPERIMENTAL
Intervention: Late contralateral CEA
Number of subjects: 534

Group type: EXPERIMENTAL
Intervention: Survival rates
Number of subjects: 534
Study: 11213546

Group type: COMPARATOR
Intervention: Fentanyl (2.0 micrograms/kg) and atropine (0.01 mg/kg) as premedication
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Remifentanil (0.2 microgram/kg/min) and atropine (0.01 mg/kg) as infusion
Number of subjects: 50
Study: 9360253

Group type: EXPERIMENTAL
Intervention: Prednisolone
Number of subjects: 112

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 112

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 112
Study: 1364952

Group type: EXPERIMENTAL
Intervention: Trans-scleral panretinal cryocoagulation combined with cyclo-cryocoagulation
Number of subjects: 38

Group type: COMPARATOR
Intervention: Cyclo-cryocoagulation
Number of subjects: 38
Study: 3881294

Group type: EXPERIMENTAL
Intervention: 5 mg Ethinylestradiol (EE) for 5 consecutive days
Number of subjects: 493

Group type: EXPERIMENTAL
Intervention: 200 micrograms Ethinylestradiol (EE) and 2 mg dl‐norgestrel (NG)
Number of subjects: 493
Study: 30755638

Group type: EXPERIMENTAL
Intervention: 3DPIM trays (3D-printed trays with inner marginal-band tissue stops)
Number of subjects: 6

Group type: COMPARATOR
Intervention: 3DP trays (3D-printed trays without tissue stops)
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: 3DPS trays (3D-printed trays with saddle-shaped tissue stops)
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: 3DPM trays (3D-printed trays with marginal-band tissue stops)
Number of subjects: 6
Study: 29419896

Group type: EXPERIMENTAL
Intervention: Excimer lamp (twice weekly)
Number of subjects: 36

Group type: COMPARATOR
Intervention: Calcipotriol-clobetasol combination (once daily)
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Excimer lamp
Number of subjects: 36

Group type: COMPARATOR
Intervention: Calcipotriol-clobetasol combination
Number of subjects: 36
Study: 27563091

Group type: EXPERIMENTAL
Intervention: Screening mechanism combining free provision of chlorine solution with household vouchers that need to be redeemed monthly.
Number of subjects: 0

Group type: COMPARATOR
Intervention: Nonvoucher free distribution program (Control).
Number of subjects: 0
Study: 24858151

Group type: EXPERIMENTAL
Intervention: Single visit root canal treatment
Number of subjects: 120

Group type: COMPARATOR
Intervention: Multi visit root canal treatment
Number of subjects: 120
Study: 22138361

Group type: EXPERIMENTAL
Intervention: Yogurt supplemented with Bifidobacterium longum BB536 (BB536Y group) for 8 weeks
Number of subjects: 32

Group type: COMPARATOR
Intervention: Milk (control group)
Number of subjects: 32
Study: 20566266

Group type: EXPERIMENTAL
Intervention: Combination of pre-notification and follow-up
Number of subjects: 880

Group type: COMPARATOR
Intervention: Pre-notification only
Number of subjects: 880

Group type: COMPARATOR
Intervention: Follow-up only
Number of subjects: 880
Study: 18036451

Group type: EXPERIMENTAL
Intervention: Sildenafil 50 mg twice per day
Number of subjects: 46

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 46
Study: 15826716

Group type: EXPERIMENTAL
Intervention: Lactitol 60 g/day
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: Rifaximin 1200 mg/day
Number of subjects: 75

Group type: COMPARATOR
Intervention: No treatment
Number of subjects: 75
Study: 12392332

Group type: EXPERIMENTAL
Intervention: Bobath approach
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Balance Performance Monitor (BPM) feedback training
Number of subjects: 40

Group type: COMPARATOR
Intervention: No specific treatment (control group)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Task-specific reach training
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: BPM training group
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Task-specific reach group
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Bobath group
Number of subjects: 40

Group type: COMPARATOR
Intervention: Untrained group
Number of subjects: 40